Physician profile
Judith A Betts
NPI 1992735120
$6,288.37
in general payments reported to CMS, 2019-2025
29 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $612 · 2021: $826 · 2022: $1,143 · 2023: $1,673 · 2024: $800 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,111.14 | 2021-2025 | |
| Amgen INC. | $817.82 | 2019-2024 | Tavneos, Parsabiv, Aranesp |
| Astrazeneca Pharmaceuticals LP | $784.25 | 2019-2023 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $746.74 | 2019-2023 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $713.32 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $408.76 | 2019-2023 | Jynarque |
| Novo Nordisk INC | $360.16 | 2024-2025 | Ozempic |
| Mallinckrodt Hospital Products INC. | $273.77 | 2022-2024 | Terlivaz, Acthar |
| Glaxosmithkline, LLC. | $170.36 | 2023 | Jesduvroq, Benlysta |
| Daiichi Sankyo INC. | $152.67 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $138.90 | 2023 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $132.50 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $106.84 | 2019-2020 | |
| Horizon Therapeutics Plc | $73.21 | 2019-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $72.17 | 2019-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.99 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $42.62 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $37.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.91 | 2023 | |
| Travere Therapeutics, INC. | $27.80 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $21.17 | 2022 | |
| Outset Medical INC | $14.47 | 2023 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Betts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.